[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hyundai Bioscience Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100639752",false,"NCT07576868","A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2)","A Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate Safety and Efficacy of CP-COV03 in Dengue Patients (Part 1) \u002F Dengue and Dengue-like Illness Patients (Part 2)","Inclusion Criteria:\n\n* Patients who are 18 years or over of age at time of screening.\n* Patients who have at least two symptoms with a score of 2 or higher within 72 h from fever onset.\n* Patients who are diagnosed with dengue by NS1 positive (Phase 2- Part 1 only). And patients who are classified as dengue, zika, influenza, COVID-19 and others (Phase 3- Part 2 only)\n\nExclusion Criteria:\n\n* Patients who show severe dengue (WHO dengue guideline C, any severe symptoms or clinical laboratory results)\n* Patients who have previously received dengue vaccine\n* Patients who have chronic medical conditions such as uncontrolled diabetes mellitus, severe asthma requiring oral steroids or admission to the hospital in the previous 6 months for cardiac disease","ALL","18 Years",{"count":18,"type":19},210,"ESTIMATED","INTERVENTIONAL",[22,23],"PHASE2","PHASE3","This is a randomized, double-blind, placebo-controlled Phase 2\u002F3 study to evaluate the efficacy, safety, and antiviral activity of CP-COV03 in adult patients with dengue infection.",[26],"Dengue",[28,29,30],"dengue","dengue treatment","dengue antiviral","RECRUITING","2026-05-04",{"date":34,"type":35},"2026-05-08","ACTUAL",{"date":37,"type":35},"2026-04-09",{"date":39,"type":19},"2027-05",{"name":41,"class":42},"Hyundai Bioscience Co., Ltd.","INDUSTRY",2,""]